Anavex Life Sciences Corp. (AVXL) is a Biological Products, (No Diagnostic Substances) stock trading at $3.04 (as of 2026-05-29), with a market capitalization of $280.80M and a trailing P/E of -6.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing drug candidates for central nervous system diseases. Its pipeline includes ANAVEX 2-73 in Phase III trials for Alzheimer’s disease and Rett syndrome, Phase II testing for Parkinson’s disease, and earlier-stage studies for other neurodegenerative indications, along with ANAVEX 3-71 in Phase I trials for dementia-related conditions.
| Price | $3.04 |
| Market Cap | $280.80M |
| P/E Ratio | -6.6 |
| Price / Book | 2.22 |
| DCF Value (model) | $-6.29 |
| DCF Upside vs Price | -306.9% |
| Return on Equity | -31.5% |
| Top Institutional Holder | BlackRock, Inc. ($23.36M) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 1 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Biological Products, (No Diagnostic Substances) |
| CEO | Christopher U. Missling |
| Employees | 42 |
| Country | US |
| IPO Date | 2006-08-02 |
Data as of 2026-05-29.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.